Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.8
3.9
Journals
Biomedicines
Special Issues
Advances in Skin Tumors: From Pathogenesis to Treatment Strategies
share announcement

Advances in Skin Tumors: From Pathogenesis to Treatment Strategies

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 30 April 2026 | Viewed by 83

Special Issue Editors

Prof. Dr. Zhongxin Yu

E-Mail Website
Guest Editor
Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Interests: pediatric skin diseases; cutaneous soft tissue tumors; molecular pathology
Dr. Sepideh Nikki Asadbeigi

E-Mail Website
Guest Editor
Department of Pathology and Dermatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Interests: melanoma; spitz neoplasm; cutaneous lymphoma; molecular pathogenesis

Special Issue Information

Dear Colleagues,

Skin tumors, encompassing both benign and malignant lesions, represent a significant global health burden, with rising incidence rates in recent years. Among malignant skin tumors, melanocytic and non-melanocytic skin neoplasms pose major clinical challenges due to their complex pathogenesis, metastatic potential, and resistance to conventional therapies. Recent advances in molecular biology, immunology, and targeted therapeutics have revolutionized our understanding of skin tumorigenesis, paving the way for innovative diagnostic and treatment strategies.

This Special Issue aims to highlight cutting-edge research on the mechanisms driving skin tumor development, progression, and metastasis, as well as emerging therapeutic approaches, including immunotherapy, targeted therapy, and personalized medicine. For this Special Issue, we welcome original research articles and reviews. Research areas may include, but are not limited to the following:

  • Molecular pathogenesis and drivers of melanocytic and non-melanocytic skin tumors;
  • Tumor microenvironment and immune evasion mechanisms;
  • Novel diagnostic tools and prognostic biomarkers;
  • Advances in targeted therapy (e.g., BRAF/MEK inhibitors, Hedgehog pathway inhibitors);
  • Immunotherapy (e.g., immune checkpoint inhibitors, CAR-T cells, vaccines);
  • Drug resistance mechanisms and overcoming therapeutic challenges;
  • Emerging technologies (e.g., AI in diagnostics, nanotechnology-based treatments).

We look forward to receiving your contributions and collaborating to advance the field of skin tumor research.

Prof. Dr. Zhongxin Yu
Dr. Sepideh Nikki Asadbeigi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • melanoma skin
  • tumor epigenetic alterations
  • genetic mutations
  • tumor microenvironment immunotherapy
  • targeted therapy
  • nanomedicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 3156 KB  
Article
Spatial Distribution and Phenotypic Profiling of Cd68+ and Cd163+ Macrophages in Melanoma Progression: Insights into Tumor Microenvironment Dynamics
by Grigory Demyashkin, Dmitrii Atiakshin, Kirill Silakov, Vladimir Shchekin, Maxim Bobrov, Matvey Vadyukhin, Tatyana Borovaya, Ekaterina Blinova, Petr Shegay and Andrei Kaprin
Biomedicines 2025, 13(9), 2178; https://doi.org/10.3390/biomedicines13092178 (registering DOI) - 5 Sep 2025
Abstract
Background: Macrophages are key components of the tumor microenvironment and play a critical role in melanoma progression. However, the dynamics of different macrophage subsets, particularly CD68+ and CD163+ populations, in relation to tumor thickness and stage remain insufficiently characterized. Objective: [...] Read more.
Background: Macrophages are key components of the tumor microenvironment and play a critical role in melanoma progression. However, the dynamics of different macrophage subsets, particularly CD68+ and CD163+ populations, in relation to tumor thickness and stage remain insufficiently characterized. Objective: This study aimed to quantitatively assess intratumoral and peritumoral CD68+ and CD163+ macrophages in cutaneous melanoma and to investigate their associations with Breslow thickness, pT stage, and AJCC stage. Methods: We conducted a retrospective cohort study of 126 patients with cutaneous melanoma (AJCC stages IA–IIID). Tumor samples were examined histologically and immunohistochemically for CD68+ and CD163+ macrophages, and quantitative analysis was performed in intratumoral and peritumoral regions. Results: This study included 126 patients with cutaneous melanoma, ranging in stage from IA to IIID. Histopathological analysis revealed that melanoma tissues were primarily composed of irregular clusters of atypical melanocytic cells infiltrating the dermis and subcutaneous fat. Immunohistochemical staining identified CD68+ and CD163+ macrophages both within the tumor and in the surrounding stroma. Macrophage infiltration significantly increased with tumor thickness (Breslow) and progression to more advanced stages. Specifically, at Breslow thickness <1.0 mm, the mean number of CD68+ macrophages in the intratumoral zone was 29.7 ± 4.3 cells, increasing to 70.3 ± 6.4 cells in tumors >4.0 mm. CD163+ macrophages showed similar trends, with a rise from 15.6 ± 2.8 cells at <1.0 mm to 39.8 ± 4.6 cells at >4.0 mm in the intratumoral zone. Additionally, macrophage density was higher in tumors with ulceration, and both CD68+ and CD163+ macrophage numbers increased progressively with tumor stage, particularly in advanced stages. The number of CD68+ macrophages at stage IA in the intratumoral zone was 21.6 ± 3.1 cells and increased to 56.4 ± 6.8 cells at stage IIID, while CD163+ macrophages rose from 13.8 ± 3.2 cells at stage IA to 36.4 ± 4.6 cells at stage IIID. This suggests that macrophage infiltration, particularly CD163+ cells, correlates with melanoma progression. Conclusions: Our findings highlight distinct spatial and phenotypic patterns of macrophage infiltration in melanoma progression. The prominent increase in CD68+ and CD163+macrophages suggests their important role in tumor-associated immunomodulation. Further studies are warranted to elucidate macrophage polarization states and their prognostic and therapeutic implications in melanoma. Full article
(This article belongs to the Special Issue Advances in Skin Tumors: From Pathogenesis to Treatment Strategies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop